Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Clovis Oncology stock

Learn how to easily invest in Clovis Oncology stock.

Clovis Oncology Inc is a biotechnology business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 413 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Clovis Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLVS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Clovis Oncology stock price (NASDAQ: CLVS)

Use our graph to track the performance of CLVS stocks over time.

Clovis Oncology shares at a glance

Information last updated 2022-07-02.
Latest market close$2.85
52-week range$0.58 - $5.92
50-day moving average $1.24
200-day moving average $2.52
Wall St. target price$3.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.08

Buy Clovis Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Clovis Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Clovis Oncology price performance over time

Historical closes compared with the close of $2.85 from 2022-07-01

1 week (2022-06-29) 66.67%
1 month (2022-06-02) N/A
3 months (2022-04-06) 2.15%
6 months (2022-01-04) -2.06%
1 year (2021-07-06) -49.02%
2 years (2020-07-06) -56.32%
3 years (2019-07-05) 14.2
5 years (2017-07-05) 93.555

Is Clovis Oncology stock undervalued or overvalued?

Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clovis Oncology's PEG ratio

Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Clovis Oncology financials

Revenue TTM $145 million
Gross profit TTM $115.3 million
Return on assets TTM -26.53%
Return on equity TTM 0%
Profit margin -178.28%
Book value $-0.56
Market capitalisation $410.1 million

TTM: trailing 12 months

Clovis Oncology share dividends

We're not expecting Clovis Oncology to pay a dividend over the next 12 months.

Clovis Oncology share price volatility

Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $0.581 up to $5.92. A popular way to gauge a stock's volatility is its "beta".

CLVS.US volatility(beta: 1.61)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 1.6103. This would suggest that Clovis Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Clovis Oncology overview

Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U. S. , the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein.

Frequently asked questions

What percentage of Clovis Oncology is owned by insiders or institutions?
Currently 1.443% of Clovis Oncology shares are held by insiders and 40.345% by institutions.
How many people work for Clovis Oncology?
Latest data suggests 413 work at Clovis Oncology.
When does the fiscal year end for Clovis Oncology?
Clovis Oncology's fiscal year ends in December.
Where is Clovis Oncology based?
Clovis Oncology's address is: 5500 Flatiron Parkway, Boulder, CO, United States, 80301
What is Clovis Oncology's ISIN number?
Clovis Oncology's international securities identification number is: US1894641000
What is Clovis Oncology's CUSIP number?
Clovis Oncology's Committee on Uniform Securities Identification Procedures number is: 189464100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site